Article
Breakingviews - Merck's cancer rush may spawn lower returns
Rating:
0.0
Views:
33
Likes:
1
Library:
1
Merck is loading up on cancer-killing arrows. The American drug company said on Thursday it signed a giant deal with Daiichi Sankyo for the rights to sell three potential drugs outside Japan. Merck will pay $4 billion upfront, up to another $1.5 billion over the next two years, and as much as $16.5 billion if the drugs pass certain sales milestones.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value